
Sun Pharmaceutical Industries reported a 27% year-on-year increase in net profit to ₹2,894 crore for the June 2026 quarter.
Despite the profit growth, the company's revenue of ₹10,500 crore fell slightly below market expectations, leading to a mixed reaction from investors.
The firm plans to focus on its specialty drug portfolio in the coming quarters to offset margin pressures and sustain its growth trajectory.